No Data
The current cycle of Traditional Chinese Medicine materials is entering a downturn phase, and pharmaceutical companies may face a cost "turning point."
In the second half of 2024, the prices of Traditional Chinese Medicine materials are expected to decline overall; the semi-annual and third quarter reports of this year show that the gross margin of some Chinese Patent Medicine listed companies has significantly decreased, indicating a notable impact of the fluctuation in Traditional Chinese Medicine material prices on costs. However, with the retreat in Traditional Chinese Medicine material prices, production costs for companies will also decrease.
Sinolink: The end of year centralized purchasing expectations are gradually being cleared, and the pharmaceutical sector行情 is expected to gradually start.
The pharmaceutical Sector is currently in a process of a triple reversal in performance, policies, and funding, with full confidence in the recovery of revenue profit growth and market resurgence of listed companies in the Sector by 2025.
Investors Three-year Losses Continue as Asymchem Laboratories (Tianjin) (SZSE:002821) Dips a Further 4.3% This Week, Earnings Continue to Decline
Featured announcements | Kanzhun revenue increased 19% year-on-year in the third quarter; China Taibao's original premium income during the year exceeded 410 billion yuan
Xinyi Glass and Xinyi Auto Glass (Hong Kong) signed a 2024 glass supply agreement; CGN Energy completed a cumulative total of 17,684.1 gigawatt-hours of power generation in the first 11 months, an increase of 1.7% over the previous year.
Gloria Ying: Some directors, senior management and core technical and business personnel increased their holdings of the company by 23.2638 million yuan
Gelonghui reported on December 11 that Asymchem Laboratories (002821.SZ) announced that as of the date of this announcement, the implementation period of this Shareholding plan has passed halfway. Some Directors, senior management, and other core technical and business personnel have cumulatively increased their holdings of the company’s shares by 344,194 shares through the centralized bidding trading system of the Shenzhen Exchange, accounting for 0.0936% of the current total share capital of the company, with a total increase amount of 23.2638 million yuan.
Bearish landing? Hong Kong stocks in the pharmaceutical sector collectively strengthen with wuxi apptec rising over 8%.
① How much impact did the biological safety legislation have on domestic pharmaceutical stocks previously? ② How do industry insiders view the subsequent development of the biological legislation?
Asymchem Laboratories (Tianjin) Co., Ltd. (SZSE:002821) Stock Catapults 26% Though Its Price And Business Still Lag The Market
No Data
